IP Library Granted Patent US 7,785,877
Granted Patent B2
US 7,785,877 · App. 11/076,399 · Granted Aug 31, 2010

Bovine immunodeficiency virus (BIV) based vectors

Assignee: Novartis AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,785,877
App. No.
11/076,399
Granted
Aug 31, 2010
Kind
B2
Abstract

This invention pertains to BIV constructs encompassing BIV combination vectors, BIV vectors and BIV packaging vectors and particularly the invention pertains to a three vector system comprising: a) a BIV vector construct including a DNA segment from a BIV genome, a packaging sequence to package RNA into virions; a promoter operably linked to the DNA segment; and a transgene operably linked to a second promoter; b) a BIV packaging vector construct comprising a BIV DNA sequence fragment comprising at least a gag gene or pol gene of BIV; a promoter operably linked to the BIV DNA fragment; and a polyadenylation sequence located downstream of the BIV DNA fragment; and c) an expression vector construct comprising a gene encoding a viral surface protein. Also provided is a method for transferring a gene of interest into a mammalian cell.

Claims (36)

1. A producer cell comprising:

(a) a first construct comprising a promoter operably linked to a BIV gag, pol or gag and pol sequences;

(b) a second construct comprising a promoter operably linked to a viral envelope sequence; and

(c) a third construct comprising:

i) a DNA segment from a BIV genome,

ii) a packaging sequence to package RNA into virions,

iii) a first promoter operably linked to the DNA segment, and

iv) a transgene operably linked to a second promoter, wherein at least one of vpw, vpy and tat is deleted from said construct.

2. A producer cell comprising:

a BIV gag, poi or gag/pol coding sequence;

a viral envelope coding sequence; and

a vector construct comprising a promoter linked to a first BIV R region, a BIV U5 element linked to the first BIV R region, a packaging sequence, a transgene, and a BIV U3 element linked to a second BIV R region, wherein the promoter initiates RNA transcription of the vector construct, wherein at least one of vpw, vpy and tat is deleted from said vector construct.

3. The cell of claim 1 wherein said packaging sequence is a BIV packaging sequence.

4. The cell of claim 1 , wherein said first promoter in said third construct is an LTR promoter.

5. The cell of claim 1 wherein said first promoter in said third construct is a CMV promoter.

6. The cell of claim 1 wherein said transgene is operably linked to a CMV promoter, a PGK promoter, or an MND promoter.

7. The cell of claim 1 , wherein said third construct further comprises a rev-response element (RRE).

8. The cell of claim 1 , wherein said third construct further comprises a central polypurine tract (cPPT).

9. The cell of claim 2 , wherein said transgene is operably linked to an internal promoter.

10. The cell of claim 2 , wherein one or more nucleotides in said U3 element are mutated or deleted to diminish or eliminate U3-mediated transcription.

11. The cell of claim 2 , wherein said packaging sequence is a BIV packaging sequence.

12. The cell of claim 2 , wherein any start codons in said packaging sequence are eliminated by deletion or mutation.

13. The cell of claim 2 , wherein said U3 element further comprises a sequence that enhances polyadenylation.

14. The cell of claim 2 , wherein said vector construct further comprises a cPPT.

15. The cell of claim 14 , wherein said cPPT is a BIV cPPT.

16. The cell of claim 2 , wherein said vector construct further comprises a 3′ polypurine tract.

17. The cell of claim 2 , wherein said vector construct further comprises an RNA transport element.

18. The cell of claim 17 , wherein said RNA transport element is a lentiviral rev response element (RRE).

19. The cell of claim 18 , wherein said lentiviral RRE is a BIV RRE.

20. The cell of claim 17 , wherein said RNA transport element is a constitutive transport element (CTE).

21. The producer cell of claim 1 , wherein vpw is deleted from said construct.

22. The producer cell of claim 1 , wherein vpy is deleted from said construct.

23. The producer cell of claim 1 , wherein tat is deleted from said construct.

24. The producer cell of claim 2 , wherein vpw is deleted from said construct.

25. The producer cell of claim 2 , wherein vpy is deleted from said construct.

26. The producer cell of claim 2 , wherein tat is deleted from said construct.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jan 21, 2021
From: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
To: WELLSTAT OPHTHALMICS CORPORATION
Reel/Frame 054983/0577 →
SECURITY AGREEMENT Recorded Sep 17, 2013
From: WELLSTAT OPHTHALMICS CORPORATION
To: PDL BIOPHARMA, INC.
Reel/Frame 031227/0182 →
SECURITY AGREEMENT Recorded Aug 15, 2013
From: WELLSTAT OPHTHALMICS CORPORATION
To: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 031030/0720 →
Continuity (4)
Division 0973483600 · Dec 12, 2000
Provisional Application 6026631800 · Dec 14, 1999
Provisional Application 6024949200 · Nov 17, 2000
Related Publication 20090093040A1 · Apr 9, 2009